Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Non-Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Non-Current Assets for 16 consecutive years, with $123000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 925.0% to $123000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123000.0 through Dec 2025, up 925.0% year-over-year, with the annual reading at $123000.0 for FY2025, 925.0% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $123000.0 at Plus Therapeutics, up from $45000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $123000.0 in Q4 2025, with the low at $12000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $28000.0, with a median of $16000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets plummeted 72.41% in 2021, then soared 925.0% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $16000.0 in 2021, then decreased by 25.0% to $12000.0 in 2022, then soared by 166.67% to $32000.0 in 2023, then crashed by 62.5% to $12000.0 in 2024, then skyrocketed by 925.0% to $123000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $123000.0, $45000.0, and $45000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.